NCT07405242 Retrograde Ascending Dissection: Intraluminal Aortic Therapy
| NCT ID | NCT07405242 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Ascending Aortic Dissection |
| Study Type | INTERVENTIONAL |
| Enrollment | 149 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 149 participants in total. It began in 2026-01-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a single-arm, open-label, multi-center clinical trial evaluating the safety and efficacy of endovascular treatment for retrograde dissection involving the ascending aorta that is not suitable for open surgery. The aim is to assess the short-term (30 days) and medium- to long-term (6 months and 12 months) safety and efficacy of endovascular treatment in patients with retrograde dissection involving the ascending aorta who are not suitable for open surgery. The study plans to include patients with dissection confirmed by imaging, with the tear located in the aortic arch or descending aorta and extending retrogradely to the ascending aorta, and the most distal segment of the dissection is at least 2 cm away from the coronary artery ostia. These patients have been evaluated by cardiac surgery and found to be unsuitable for open surgery, with significant risks or risks outweighing benefits associated with open surgery. This is a single-arm, open-label, multi-center study, and no blinding or randomization will be used, nor will stratification factors be set. After successful screening, the subjects will undergo endovascular treatment for aortic dissection (stent implantation) during the operation. The subjects will be followed up for one year after the operation, and the safety and efficacy of endovascular treatment for retrograde dissection involving the ascending aorta will be evaluated based on the subjects' survival status, the occurrence of surgery and disease-related complications, and the recovery of the disease.
Eligibility Criteria
Inclusion Criteria: * Voluntary participation in the clinical trial; The individual fully understands and is informed of this study and has signed the informed consent form; Willing to follow and be able to complete all trial procedures * Age ≥ 65 years old, both male and female are eligible * Confirmed by imaging to be retrograde tear aortic dissection, that is, the tear site is located at the aortic arch or descending aorta, and the retrograde tear involves the ascending aorta. The farthest segment of the dissection tear is ≥ 2 cm from the coronary artery outlet * Evaluation by cardiac surgery indicates that open surgical treatment is not suitable, performing open surgery poses significant risks or the risks outweigh the benefits * Arterial access conditions are permitted, without severe stenosis or distortion, and the stent delivery system can be smoothly introduced; Exclusion Criteria: * Severe organ ischemia or functional failure, which, after assessment, is considered to have an extremely poor prognosis and cannot benefit from endovascular treatment, such as extensive cerebral infarction or cerebral hemorrhage, resulting in irreversible severe neurological deficits, acute extensive ischemic necrosis of the mesenteric arteries, acute liver and kidney failure; * Planned to undergo aortic valve repair/replacement or coronary artery interventional therapy within 30 days; * Mechanical heart valve present at the aortic valve position; * Aortic valve regurgitation degree ≥ 3+ or 4+; * Known severe allergy to contrast agents or stent materials (such as nickel-titanium alloys, polyester, etc.); * Severe systemic infection that may lead to infection after stent implantation; * Severe coagulation dysfunction, which, after correction, still cannot meet the surgical requirements, or has bleeding tendencies; * Complicated with other serious diseases or malignant tumors, with a predicted survival period of less than 12 months; * Pregnant or lactating women; * With mental illness or cognitive impairment, unable to understand and cooperate with the study; * Already participating in other ongoing interventional clinical studies; * Other situations judged by the investigator as not suitable for inclusion in the study;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07405242 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Ascending Aortic Dissection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07405242 currently recruiting?
Yes, NCT07405242 is actively recruiting participants. Contact the research team at yanjy0117@gmail.com for enrollment information.
Where is the NCT07405242 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07405242 clinical trial?
NCT07405242 is sponsored by Ruijin Hospital. The trial plans to enroll 149 participants.